Exelixis Enters Settlement And License Agreement For CABOMETYX Patent Litigation With Teva Pharmaceuticals Development And Teva Pharmaceuticals USA
Portfolio Pulse from Benzinga Newsdesk
Exelixis has entered into a settlement and license agreement for CABOMETYX patent litigation with Teva Pharmaceuticals Development and Teva Pharmaceuticals USA.
July 24, 2023 | 5:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exelixis has settled its patent litigation with Teva Pharmaceuticals, which could potentially reduce legal costs and uncertainty for the company.
The settlement of the patent litigation could reduce legal costs and uncertainty for Exelixis. This could potentially have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Teva Pharmaceuticals has settled its patent litigation with Exelixis, which could potentially reduce legal costs and uncertainty for the company.
The settlement of the patent litigation could reduce legal costs and uncertainty for Teva Pharmaceuticals. This could potentially have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100